FDA warns CytoDyn over video promoting unapproved leronlimab as safe and effective for COVID-19.
What happened
FDA's Office of Prescription Drug Promotion reviewed a September 22, 2021 video interview with Dr. Nader Pourhassan that was linked on CytoDyn's website. In the video, he promoted leronlimab, an investigational new drug, as safe and effective for COVID-19 and made claims about survival and trial results. FDA said leronlimab was not approved or authorized and that available data did not support clinical benefit for COVID-19.
What FDA found
The video promoted leronlimab, an investigational drug, as safe and effective for COVID-19 before FDA approval or authorization.
21 CFR 312.7(a)The promotional video described a prescription use without adequate directions for safe lay use, so leronlimab was misbranded.
section 502(f)(1) of the FD&C ActThe company's actions violated the FD&C Act by introducing or delivering a misbranded drug.
section 301(a) of the FD&C ActThe video made conclusory and misleading claims that mischaracterized clinical trial data for leronlimab in COVID-19.
section 502(f)(1) of the FD&C Act
What FDA wants
OPDP asks CytoDyn to stop the violations and to send a written response within 15 working days of receipt. The response must address the concerns, list other promotional communications with similar claims, explain plans to discontinue them or cease distribution, and include a plan for corrective communications.
Who should pay attention
- drug sponsors and investigators
- medical communications and investor relations teams
- clinicians and patients considering COVID-19 treatments
This is a summary. Read the original letter on fda.gov.